Mesoblast Limited (MESO) Stock Price & Analysis
Mesoblast Limited (MESO) closed at USD 13.95 on Thursday, October 15, 2026, up 1.16% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 13.79; the Oct 15, 2026 session ranged USD 13.5–14 on volume of 237,266 shares. Market capitalization is $1.81B, with a 52-week range of USD 13.05–21.5 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MESO.md
Key facts (MESO)
- Analysts: Strong Buy (mean 1.33 on a 1–5 scale) (3 analysts), mean target USD 37 (range 35–39).
- Total return with dividends: 1Y -22.9% vs S&P 500 +18.1%; 5Y +22.8% vs S&P 500 +85.1%.
- Next earnings: 2026-08-26, EPS estimate USD -0.08, revenue estimate $54.9M.
Analysts (MESO)
Consensus Strong Buy (mean 1.33 on a 1–5 scale), 3 analysts; mean target USD 37 (low 35, high 39).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Piper Sandler | Target raised | Overweight | $35 → $39 |
Total return (dividends reinvested) (MESO)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -22.9% | +22.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -22.9% | +4.2% |
| Volatility (annualized) | 53.9% | 85.3% |
| Max drawdown | -37.1% (Jan 2026→Jun 2026) | -86.1% (Nov 2021→Jan 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 13.95 |
|---|---|
| Change | ▲ 1.16% (up) |
| Previous Close | USD 13.79 |
| Open | USD 13.56 |
| Day Range | USD 13.5 – 14 |
| 52-Week Range | USD 13.05 – 21.5 |
| Volume | 237,266 shares |
| Market Cap | $1.81B |
| Exchange | NMS |
Technical Analysis (MESO)
Nexqual's technical model rates MESO "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.35 (neutral) |
| vs SMA50 | Below (USD 15.67) |
| MACD | -0.49 (negative) |
Analyst Ratings (MESO)
Wall Street analysts rate MESO "Strong Buy" based on 3 analysts, with a mean price target of USD 37 (range USD 35–39), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 37 |
| High Target | USD 39 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (MESO)
| Next Earnings Date | 2026-08-26 |
|---|---|
| Revenue Estimate | $54.86M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (MESO)
| Total Revenue | $120.25M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +390.70% |
| Gross Margin | +80.02% |
| Operating Margin | -33.28% |
| Profit Margin | -47.82% |
| ROE | -9.86% |
| Debt / Equity | 0.22 |
| Current Ratio | 2.44 |
| Total Cash | $102.91M |
| Total Debt | $127.33M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (MESO)
Nexqual rates Mesoblast Limited's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +537% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 80%, operating -33% |
| Balance Sheet | Strong — $103M cash vs $127M debt |
| Cash Flow | Weak — Operating cash flow -$44M (TTM) |
| Efficiency | Critical — ROE -10%, ROA -4.1% |
Ownership (MESO)
| Insider Ownership | +57.38% |
|---|---|
| Institutional Ownership | +3.27% |
| Shares Outstanding | 129.85M |
| Float | 86.11M |
| Short % of Float | +3.48% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (MESO)
Mesoblast Limited is led by Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) (age 68), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) (age 68) |
|---|---|
| Chief Medical Officer & Executive Director | Eric A. Rose (age 74) |
Major Backers & Investors (MESO)
Notable institutional backers of Mesoblast Limited include Morgan Stanley, Susquehanna International Group, LLP, Goldman Sachs, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 0.55% |
| Susquehanna International Group, LLP | 0.35% |
| Goldman Sachs | 0.3% |
| BNP Paribas Asset Management Holding S.A. | 0.2% |
| UBS Group AG | 0.15% |
| Arax Advisory Partners | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.92% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt